NIH: Strategic Timing of Antiretroviral Treatment (START) (UM1)PAR-14-329
The purpose of this limited competition Funding Opportunity Announcement (FOA) is to continue support to complete the Strategic Timing of Antiretroviral Treatment (START) trial. START is a randomized clinical trial to determine if immediate initiation of antiretroviral treatment (ART) in HIV-positive patients is superior in delaying the occurrence of AIDS, non-AIDS events and death. - See more at: http://grants.nih.gov/grants/guide/pa-files/PAR-14-329.html#_3._Additional_Information
USC may only submit one application in response to this program announcement. Your application submission MUST be coordinated with the Office of the Vice President for Research. Please send a two page abstract via email to Richard White (firstname.lastname@example.org) by October 15, 2013. In addition to the 2-page abstract, you should also submit a biosketch for the PI.
NSF indicates that a letter of intent is not applicable and a full proposal is due by November 19, 2014. For more information: http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-10-007.html